Prakash Balendu, Parikh Purvish M, Pal Sanjoy K
V C P Cancer Research Foundation (Scientific & Industrial Research Organization), Dehradun, India.
J Ayurveda Integr Med. 2010 Jul;1(3):215-8. doi: 10.4103/0975-9476.72618.
A 47 year old diabetic male patient was diagnosed and treated for high risk AML-M3 at Tata Memorial Hospital (BJ 17572), Mumbai in September 1995. His bone marrow aspiration cytology indicated 96% promyelocytes with abnormal forms, absence of lymphocytic series and myeloperoxide test 100% positive. Initially treated with ATRA, he achieved hematological remission on day 60, but cytogenetically the disease persisted. The patient received induction and consolidated chemotherapy with Daunorubicin and Cytarabine combination from 12.01.96 to 14.05.96, following which he achieved remission. However, his disease relapsed in February 97. The patient was given two cycles of chemotherapy with Idarubicine and Etoposide, after which he achieved remission. His disease again relapsed in December 97. The patient then refused more chemotherapy and volunteered for a pilot Ayurvedic study conducted by the Central Council for Research in Ayurveda and Siddha, New Delhi. The patient was treated with a proprietary Ayurvedic medicine Navajeevan, Kamadudha Rasa and Keharuba Pisti for one year. For the subsequent 5 years the patient received three months of intermittent Ayurvedic treatment every year. The patient achieved complete disease remission with the alternative treatment without any adverse side effects. The patient has so far completed 13 years of survival after the start of Ayurvedic therapy.
一名47岁的男性糖尿病患者于1995年9月在孟买的塔塔纪念医院(BJ 17572)被诊断为高危急性早幼粒细胞白血病(AML-M3)并接受治疗。他的骨髓穿刺细胞学检查显示96%的早幼粒细胞形态异常,淋巴细胞系列缺失,髓过氧化物酶试验100%阳性。最初接受全反式维甲酸(ATRA)治疗,他在第60天实现了血液学缓解,但细胞遗传学上疾病仍持续存在。该患者于1996年1月12日至1996年5月14日接受了柔红霉素和阿糖胞苷联合诱导及巩固化疗,之后实现缓解。然而,他的疾病在1997年2月复发。该患者接受了两个疗程的伊达比星和依托泊苷化疗,之后实现缓解。他的疾病在1997年12月再次复发。然后该患者拒绝了更多化疗,并自愿参加了由新德里阿育吠陀和悉达研究中央理事会开展的一项阿育吠陀试点研究。该患者用一种专利阿育吠陀药物Navajeevan、Kamadudha Rasa和Keharuba Pisti治疗了一年。在随后的5年里,该患者每年接受3个月的间歇性阿育吠陀治疗。通过替代治疗,该患者实现了疾病完全缓解,且没有任何不良副作用。到目前为止,该患者自阿育吠陀治疗开始后已存活13年。